Insmed(INSM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

INSM Insmed

交易中 03-04 13:18:54 EST

148.40

+1.40

+0.95%

最高149.14	最低146.73	成交量61.29万
今开146.74	昨收147.00	日振幅1.64%
总市值319.88亿	流通市值286.41亿	总股本2.16亿
成交额9,071万	换手率0.32%	流通股本1.93亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"INSM","market":"US","secType":"STK","nameCN":"Insmed","latestPrice":148.4,"timestamp":1772648332205,"preClose":147,"halted":0,"volume":612898,"delay":0,"changeRate":0.009523809523809563,"floatShares":193000000,"shares":215551896,"eps":-6.42,"marketStatus":"交易中","change":1.4,"latestTime":"03-04 13:18:54 EST","open":146.74,"high":149.14,"low":146.73,"amount":90709008.19266,"amplitude":0.016395,"askPrice":148.5,"askSize":319,"bidPrice":148.35,"bidSize":116,"shortable":3,"etf":0,"ttmEps":-6.42,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1772658000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":959832000000,"exchange":"NASDAQ","adjPreClose":147,"preHourTrading":{"tag":"盘前","latestPrice":146.52,"preClose":147,"latestTime":"09:27 EST","volume":2017,"amount":296472.21424,"timestamp":1772634470031,"change":-0.48,"changeRate":-0.003265,"amplitude":0.011701},"postHourTrading":{"tag":"盘后","latestPrice":147,"preClose":147,"latestTime":"19:08 EST","volume":26658,"amount":3918720.31,"timestamp":1772582885765,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.409453,"impliedVol":0.4451,"impliedVolPercentile":0.259},"requestUrl":"/m/hq/s/INSM","defaultTab":"news","newsList":[{"id":"1193003476","title":"Brensocatib获英国MHRA批准，成为首个专治非囊性纤维化支气管扩张症的药物，适用于12岁及以上患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1193003476","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193003476?lang=zh_cn&edition=full","pubTime":"2026-02-23 17:24","pubTimestamp":1771838688,"startTime":"0","endTime":"0","summary":"英国药品和保健品监管局（MHRA）已正式批准Brensocatib作为全球首款专门用于治疗12岁及以上非囊性纤维化支气管扩张症的药物。这一里程碑式的批准为长期缺乏针对性疗法的患者群体带来了新的希望。Brensocatib通过抑制中性粒细胞丝氨酸蛋白酶来减缓疾病进展，其独特的作用机制标志着支气管扩张症治疗领域的重大突破。该药物由生物制药公司Insmed研发，将显著改善患者的生活质量并降低急性加重风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0320765992.SGD","INSM","LU0053671581.USD","LU0109394709.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"1188243271","title":"财报前瞻｜Insmed本季度营收预计增118.23%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1188243271","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188243271?lang=zh_cn&edition=full","pubTime":"2026-02-12 10:13","pubTimestamp":1770862398,"startTime":"0","endTime":"0","summary":"Insmed将于2026年02月19日发布最新季度财报，市场关注产品销售增长与费用控制的权衡以及研发进展对利润的影响。市场一致预期显示，本季度Insmed总营收预计为2.24亿美元，同比增长118.23%；毛利率暂无权威一致预测；净利润或净利率无一致预测；调整后每股收益预计为-1.10美元，同比增长5.93%。从近期机构观点来看，偏乐观的声音占据主导。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Insmed本季度营收预计增118.23%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM"],"gpt_icon":0},{"id":"1179116674","title":"Insmed 2025年初步营收6.06亿美元，同比增长67%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179116674","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179116674?lang=zh_cn&edition=full","pubTime":"2026-01-09 21:06","pubTimestamp":1767964011,"startTime":"0","endTime":"0","summary":"1月9日，生物制药公司Insmed盘前涨超11%，此前该公司宣布了2025年强劲的初步收入结果，其中BRINSUPRI成功上市和ARIKAYCE销售超出预期成为亮点。Insmed 2025年初步未经审计的总收入达到6.064亿美元，较2024年增长67%，超过了5.22亿美元的市场共识预期。公司预计2026年ARIKAYCE全球收入将在4.5亿至4.7亿美元之间。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"87f58df0cea45f9dc7f6df99dc1f4be0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Insmed 2025年初步营收6.06亿美元，同比增长67%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM"],"gpt_icon":1},{"id":"1159401717","title":"Insmed股票在盘前交易中下跌20.1%，因公司中期研究失败后停止鼻窦药物开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1159401717","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159401717?lang=zh_cn&edition=full","pubTime":"2025-12-18 18:30","pubTimestamp":1766053814,"startTime":"0","endTime":"0","summary":"Insmed股票在盘前交易中下跌20.1%，因公司中期研究失败后停止鼻窦药物开发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f9f3169eeaffd188a4d97d9b846e92ea","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","INSM","LU0053671581.USD","LU0889565916.HKD","LU0320765992.SGD","BK4139"],"gpt_icon":0},{"id":"1188873548","title":"美股夜盘 | 美光科技绩后涨超8%，大麻股CGC涨超13%；INSM暴跌18%，CART跌近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188873548","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188873548?lang=zh_cn&edition=full","pubTime":"2025-12-18 09:05","pubTimestamp":1766019931,"startTime":"0","endTime":"0","summary":"12月18日，美股夜盘时段，$美光科技(MU)$涨超8%，芯片需求旺盛，业绩与指引双双“爆表”；受此消息影响，存储概念股集体走高，$SanDisk Corp(SNDK)$涨超5%，$西部数据(WDC)$涨超2%。大麻股夜盘上涨，$Canopy Growth(CGC)$涨超13%，Tilray涨超5%。报道称特朗普拟于周四签署行政令重新归类大麻；医疗用品供应商Medline夜盘跌超2%，其上市首日股价涨超40%；","market":"us","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CART","BK4566","BK4579","BK4532","BK4588","BK4605","BK4141","BK4533","BK4527","BK4554","BK4512","INSM","BK4585","MDLN","BK4543","MU","BK4553","TLRY","BK4575"],"gpt_icon":0},{"id":"1173952258","title":"Insmed收购二期临床准备的单克隆抗体 以应对潜在的呼吸系统及免疫与炎症相关指示","url":"https://stock-news.laohu8.com/highlight/detail?id=1173952258","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173952258?lang=zh_cn&edition=full","pubTime":"2025-12-18 05:03","pubTimestamp":1766005391,"startTime":"0","endTime":"0","summary":"Insmed收购二期临床准备的单克隆抗体 以应对潜在的呼吸系统及免疫与炎症相关指示","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM","LU0053671581.USD","BK4139","LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD"],"gpt_icon":0},{"id":"1168222595","title":"Insmed Inc - Brensocatib在CRSSNP的2B期Birch研究未达到主要或次要疗效指标","url":"https://stock-news.laohu8.com/highlight/detail?id=1168222595","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168222595?lang=zh_cn&edition=full","pubTime":"2025-12-18 05:03","pubTimestamp":1766005391,"startTime":"0","endTime":"0","summary":"Insmed Inc - Brensocatib在CRSSNP的2B期Birch研究未达到主要或次要疗效指标","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","INSM","LU0889565916.HKD","LU0053671581.USD","BK4139","LU0109394709.USD"],"gpt_icon":0},{"id":"1131212462","title":"纳斯达克公司：阿尔尼拉姆制药、Ferrovial、Insmed、单片电源系统、希捷科技、西部数据将被纳入纳斯达克100指数","url":"https://stock-news.laohu8.com/highlight/detail?id=1131212462","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131212462?lang=zh_cn&edition=full","pubTime":"2025-12-13 09:09","pubTimestamp":1765588155,"startTime":"0","endTime":"0","summary":"纳斯达克公司：阿尔尼拉姆制药、Ferrovial、Insmed、单片电源系统、希捷科技、西部数据将被纳入纳斯达克100指数","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0edbc198404a72334f079a67157af149","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0081259029.USD","LU0353189680.USD","LU2473716301.USD","LU2931357623.SGD","LU2272731600.USD","LU0109391861.USD","ALNY","SG9999014013.SGD","BK4170","LU1861220033.SGD","LU1267930730.SGD","IE00B64PRP62.GBP","LU1069347547.HKD","LU2095319765.USD","IE00BN0W2T93.GBP","LU2272731782.SGD","LU0889565916.HKD","LU1823568750.SGD","LU0203347892.USD","IE00BD6J9T35.USD","LU1235294995.USD","BK4588","BK4112","BK4548","LU0320765992.SGD","LU2210150020.SGD","LU0053671581.USD","LU0708995401.HKD","LU0957808578.USD","BK4585","LU0203345920.USD","IE00B19Z9Z06.USD","LU1992135399.USD","LU1861215975.USD","LU1642822529.SGD","INSM","STX","LU1852331112.SGD","NDAQ","IE00BN0W2W23.USD","LU0006061336.USD","LU2322448957.HKD","LU0353189763.USD","LU0314104364.USD","LU2322448791.USD","LU0114720955.EUR","BK4141","LU1046421795.USD","LU0056508442.USD","LU1815336760.USD","BK4512","LU2290526834.HKD","LU2360107168.USD","LU2089985449.USD","LU2210149790.SGD","IE00B19Z9P08.USD","LU0672654240.SGD","LU2087625088.SGD","IE00BN0W2V16.EUR","LU0274383776.USD","LU1670627923.USD","LU1992135472.HKD","SG9999014005.SGD","LU0476273544.USD","WDC","IE00B894F039.SGD","LU2360106780.USD","LU1670628061.USD","IE00BGHQF748.EUR","LU1035773651.USD","LU0882574055.USD","IE00BKPKM429.USD","LU2250418816.HKD","LU0444971666.USD","LU0320765059.SGD","LU0444973449.USD","BK4139","IE00B3QW5Z07.USD","LU2272731865.HKD","SG9999014021.USD","MPWR","SG9999014039.USD"],"gpt_icon":0},{"id":"1197329900","title":"Insmed将于2026年初与欧盟当局互动，确保合格患者获取Brinsupri","url":"https://stock-news.laohu8.com/highlight/detail?id=1197329900","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197329900?lang=zh_cn&edition=full","pubTime":"2025-11-19 00:03","pubTimestamp":1763481792,"startTime":"0","endTime":"0","summary":"Insmed将于2026年初与欧盟当局互动，确保合格患者获取Brinsupri","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","LU0109394709.USD","LU0889565916.HKD","INSM","BK4139","LU0320765992.SGD"],"gpt_icon":0},{"id":"1121135608","title":"欧洲委员会批准Brinsupri™（Brensocatib）作为欧盟唯一获批的非囊性纤维化支气管扩张症治疗药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1121135608","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121135608?lang=zh_cn&edition=full","pubTime":"2025-11-19 00:01","pubTimestamp":1763481679,"startTime":"0","endTime":"0","summary":"欧洲委员会批准Brinsupri™（Brensocatib）作为欧盟唯一获批的非囊性纤维化支气管扩张症治疗药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM","LU0053671581.USD","LU0889565916.HKD","BK4139","LU0109394709.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2576055837","title":"EMA十月药品审评会议：赛诺菲(SNY.US)、Insmed(INSM.US)等公司新药获上市推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2576055837","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576055837?lang=zh_cn&edition=full","pubTime":"2025-10-17 21:29","pubTimestamp":1760707780,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，在本周召开的会议上，欧洲药品管理局的专家小组对赛诺菲与Insmed的两款新药做出了推荐在该地区上市的积极意见。除了推荐新药获批外，该委员会还否决了赛诺菲的一款新药，并推荐了8项新的药品适应症扩展申请。赛诺菲表示，这一决定基于该公司关键的LUNA 3期临床试验。该公司表示，CHMP的这一决定令人失望，并将寻求对该决定进行重新审查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356643.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EMA","BK4007","LU0320765992.SGD","LU0109394709.USD","BK4139","SNY","BK4588","BK4585","BK4081","LU0889565916.HKD","IE00BFXG1179.USD","LU0053671581.USD","INSM"],"gpt_icon":0},{"id":"1135371274","title":"CHMP建议欧盟批准Brinsupri™（Brensocatib）用于非囊性纤维化支气管扩张症的治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1135371274","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135371274?lang=zh_cn&edition=full","pubTime":"2025-10-17 19:01","pubTimestamp":1760698885,"startTime":"0","endTime":"0","summary":"CHMP建议欧盟批准Brinsupri™（Brensocatib）用于非囊性纤维化支气管扩张症的治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","INSM","LU0053671581.USD","LU0320765992.SGD","BK4139","LU0109394709.USD"],"gpt_icon":0},{"id":"1165253215","title":"高盛将沃尔玛、瓦莱罗能源加入9月“确信名单”，还有这些公司入选","url":"https://stock-news.laohu8.com/highlight/detail?id=1165253215","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165253215?lang=zh_cn&edition=full","pubTime":"2025-09-03 13:45","pubTimestamp":1756878304,"startTime":"0","endTime":"0","summary":"高盛在9月的确信名单中新增了四只股票，其中既包括美国一些最知名的品牌，也有部分能源股。不过，高盛指出，移出名单并不一定意味着其对相关股票的基本投资评级发生了改变。高盛根据营收增长、当前股息收益率等多重指标，认为这些公司具有投资吸引力。截至目前，该股年内已上涨 8%。高盛对沃尔玛的“买入”评级与华尔街整体观点一致。高盛认为，其股价还有 7% 的上行空间。","market":"us","thumbnail":"https://community-static.tradeup.com/news/ebd93ab0fd3bcb1f3363cb69f435ed88","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/ebd93ab0fd3bcb1f3363cb69f435ed88"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"高盛将沃尔玛、瓦莱罗能源加入9月“确信名单”，还有这些公司入选","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WMT","CDNS","INSM","VLO","GEV","MCD","VNOM"],"gpt_icon":1},{"id":"2514113720","title":"Insmed(INSM.US)获加拿大皇家银行首次覆盖，给予优于大市评级, 目标价100.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514113720","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514113720?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:23","pubTimestamp":1740500610,"startTime":"0","endTime":"0","summary":"Insmed(INSM.US)获加拿大皇家银行首次覆盖，给予优于大市评级, 目标价100.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/26002348385754.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["INSM"],"gpt_icon":0},{"id":"2513875615","title":"Insmed Incorporated2024财年实现净利润-9.14亿美元，同比减少21.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513875615","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513875615?lang=zh_cn&edition=full","pubTime":"2025-02-24 00:00","pubTimestamp":1740326449,"startTime":"0","endTime":"0","summary":"2月24日，Insmed Incorporated公布财报，公告显示公司2024财年净利润为-9.14亿美元，同比减少21.87%；其中营业收入为3.64亿美元，同比增加19.34%，每股基本收益为-5.57美元。从资产负债表来看，Insmed Incorporated总负债17.40亿美元，其中短期债务16.50百万美元，资产负债比为1.17，流动比率为5.45。机构评级：截至2025年2月24日，当前有15家机构对Insmed Incorporated目标价做出预测，其中目标均价为96.93美元，其中最低目标价为89.00美元，最高目标价为108.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000118a250ce02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000118a250ce02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INSM"],"gpt_icon":0},{"id":"2513691213","title":"Truist Securities：维持Insmed(INSM.US)评级，由买入调整至买入评级, 目标价由105.00美元调整至108.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513691213","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513691213?lang=zh_cn&edition=full","pubTime":"2025-02-22 01:41","pubTimestamp":1740159669,"startTime":"0","endTime":"0","summary":"Truist Securities：维持Insmed(INSM.US)评级，由买入调整至买入评级, 目标价由105.00美元调整至108.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/22014148321070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["INSM"],"gpt_icon":0},{"id":"1119035536","title":"异动解读 | 盘中狂泻5.11%!Insmed财报营收增长放缓、亏损扩大引发股价大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1119035536","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119035536?lang=zh_cn&edition=full","pubTime":"2025-02-20 22:37","pubTimestamp":1740062235,"startTime":"0","endTime":"0","summary":"在今日盘中交易中,生物制药公司Insmed股价大跌5.11%,引发了市场广泛关注。据分析,这与公司2024年第四季度财报表现不佳有很大关系。\n\n具体来看,Insmed上一季度销售额虽然达到1.0444亿美元、高于预期,但同比增长仅为24.79%,增速明显放缓。更为重要的是,Insmed当季每股亏损高达1.32美元,远高于分析师预期的1.17美元亏损。\n\n营收增长放缓加之亏损扩大,令投资者对Insmed的业务前景和盈利能力产生质疑,从而引发公司股价在盘中大幅下跌。Insmed面临着业绩增长乏力、成本控制不佳等一系列问题,当务之急是尽快扭转局面、实现盈利,从而重拾投资者信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["INSM"],"gpt_icon":0},{"id":"1148282852","title":"Insmed 2024年第四季度每股亏损$(1.32)，低于$(1.17)的预期；销售额$1.0444亿，高于$1.0179亿的预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1148282852","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148282852?lang=zh_cn&edition=full","pubTime":"2025-02-20 20:09","pubTimestamp":1740053345,"startTime":"0","endTime":"0","summary":"Insmed  报告了季度每股亏损$，比分析师共识预期的$低了12.82%。这一亏损相比去年同期的每股亏损$减少了3.13%。公司报告的季度销售额为$1.0444亿，高于分析师共识预期的$1.0179亿，增长了2.60%。以上内容来自Benzinga Earnings专栏，原文如下：$Insmed$  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 12.82 percent. This is a 3.13 percent decrease over losses of $ per share from the same period last year.  The company reported quarterly sales of $104.44 million which beat the analyst consensus estimate of $101.79 million by 2.60 percent.  This is a 24.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Insmed 2024年第四季度每股亏损$(1.32)，低于$(1.17)的预期；销售额$1.0444亿，高于$1.0179亿的预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM"],"gpt_icon":1},{"id":"2509774987","title":"小摩：维持Insmed(INSM.US)评级，由增持调整至增持评级, 目标价由83.00美元调整至92.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509774987","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509774987?lang=zh_cn&edition=full","pubTime":"2025-02-08 05:21","pubTimestamp":1738963318,"startTime":"0","endTime":"0","summary":"小摩：维持Insmed(INSM.US)评级，由增持调整至增持评级, 目标价由83.00美元调整至92.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/08052148031920.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["INSM"],"gpt_icon":0},{"id":"2509274305","title":"大摩：维持Insmed(INSM.US)评级，由增持调整至增持评级, 目标价由85.00美元调整至90.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509274305","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509274305?lang=zh_cn&edition=full","pubTime":"2025-02-06 22:22","pubTimestamp":1738851741,"startTime":"0","endTime":"0","summary":"大摩：维持Insmed(INSM.US)评级，由增持调整至增持评级, 目标价由85.00美元调整至90.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/06222248001920.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["INSM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.insmed.com","stockEarnings":[{"period":"1week","weight":-0.0733},{"period":"1month","weight":-0.0629},{"period":"3month","weight":-0.2891},{"period":"6month","weight":0.0314},{"period":"1year","weight":0.9269},{"period":"ytd","weight":-0.1554}],"compareEarnings":[{"period":"1week","weight":-0.0102},{"period":"1month","weight":-0.0168},{"period":"3month","weight":-0.0052},{"period":"6month","weight":0.0481},{"period":"1year","weight":0.1654},{"period":"ytd","weight":-0.0023}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Insmed Incorporated于1999年11月29日在弗吉尼亚州联邦注册成立，其主要行政办公室均位于新泽西州桥水。Insmed是一家以人为本的生物制药公司，致力于提供一流的首创疗法，以改变患有严重疾病的患者的生活。其商业组合和临床管线专注于三个治疗领域：呼吸系统、免疫学和炎症，以及神经和其他罕见。","yearOnYearQuotes":[{"month":1,"riseRate":0.457143,"avgChangeRate":0.066603},{"month":2,"riseRate":0.4,"avgChangeRate":0.075433},{"month":3,"riseRate":0.361111,"avgChangeRate":-0.052774},{"month":4,"riseRate":0.4,"avgChangeRate":0.04767},{"month":5,"riseRate":0.4,"avgChangeRate":0.067566},{"month":6,"riseRate":0.542857,"avgChangeRate":0.027147},{"month":7,"riseRate":0.485714,"avgChangeRate":0.004271},{"month":8,"riseRate":0.4,"avgChangeRate":-0.021648},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032075},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.015562},{"month":11,"riseRate":0.657143,"avgChangeRate":0.105034},{"month":12,"riseRate":0.457143,"avgChangeRate":0.040841}],"exchange":"NASDAQ","name":"Insmed","nameEN":"Insmed"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Insmed(INSM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Insmed(INSM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Insmed,INSM,Insmed股票,Insmed股票老虎,Insmed股票老虎国际,Insmed行情,Insmed股票行情,Insmed股价,Insmed股市,Insmed股票价格,Insmed股票交易,Insmed股票购买,Insmed股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Insmed(INSM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Insmed(INSM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}